Hepatitis B and C in Hematopoietic Stem Cell Transplant
Author Information
Author(s): Anna Locasciulli, Barbara Montante, Emanuela Morelli, Virginia Gulino, Anna Proia, Maria Beatrice Pinazzi
Primary Institution: San Camillo Hospital
Conclusion
Patients undergoing stem cell transplantation are at risk for hepatitis B and C reactivation, which can lead to severe liver complications.
Supporting Evidence
- More than sixty percent of HBsAg-positive patients reactivate after transplant.
- 3% of patients develop acute severe liver failure post-transplant.
- 81% risk of hepatitis B reactivation at 24 months after allogeneic HSCT.
Takeaway
This study shows that people who get stem cell transplants can get sick from hepatitis B or C, which can hurt their liver.
Methodology
The study reviewed cases of patients undergoing HSCT and analyzed the prevalence and outcomes of HBV and HCV infections.
Limitations
The study may not account for all geographic variations in HBV and HCV prevalence.
Participant Demographics
Patients undergoing allogeneic or autologous stem cell transplantation.
Statistical Information
P-Value
0.3
Statistical Significance
p = 0.3
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website